Abstract
these pathways define novel, relevant, recurrent and systematic ASD biology. At sub-23 pathway level, most variants disrupt the pathway-related gene functions, and multiple 24 interacting variants spotlight key modules, e.g. cAMP second-messenger system and 25 mGluR signaling regulation by GRK in synapses. At super-pathway level, these distinct 26 pathways are highly interconnected, and further converge to a few biology themes, i.e. 27 synaptic function, morphology and plasticity. Therefore, ASD is a not just multi-genic 28 but a multi-pathway disease.
Introduction

1
Autism spectrum disorder (ASD) covers a range of complex genetic diseases. Genome 2 wide molecular profiling is a proven strategy for complex disease studies. Indeed, 3 thousands of genomic variants or loci have been identified as potential ASD causes [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . 4 These results confirm the genetic complexity of ASD and provide valuable biological 5 insights. Yet greater challenge remains: how to turn these enormous datasets into solid 6 and systematic understanding of the disease mechanism, i.e. biologically relevant 7 molecular pathways, not just a list of associated genes, their groups or networks? In fact, 8 this is the common problem remaining for all genome wide studies or complex diseases, 9 not just ASD. 10 Recently, two whole exome studies under two consortia, the Simons Simplex Collection 11 (SSC) 10, 13 and the Autism Sequencing Consortium (ASC) 11, 14 , analyzed thousands of 12 ASD families or cases-controls producing a vast amount of genetic data. These efforts 13 identified thousands of rare mutations and firmly established their roles in ASD 15 .
14 Because these variants rarely recur, major challenges remain as to: 1) evaluate the disease 15 association of individual variants; 2) pinpoint most driver events from a huge pool of 16 passengers; 3) replicate independent studies, or 4) verify their results systematically. 17 Despite the important and inspiring discoveries, a coherent and systematic understanding 18 of autism biology has not been achieved with these enormous studies 16 .
19
To address these challenges, we devised a novel integrated analysis across multiple levels, with rare events. 27 We applied this approach to both SSC 10 Table 1 and Table S4 . We applied the same selection procedure to 4 siblings in SSC for control.
5
ASD mutations from different cohorts do not replicate at variant level, but increasingly 6 do so at the gene and pathway level (Fig. 1a) . replicate at all 3 levels, and do not converge (Fig. 1b) . 16 Besides direct replication, pathway level analysis show extra reproducability ( Fig. 1c-d ).
17
Pathway analysis statistics (-log 10 P-val) are highly correlated between SSC and ASC
18
(R 2 =0.570), but not so (R 2 =0.030) between probands and siblings in SSC.
19
The actual replicability between studies should be even higher given that 1) the genetic 20 background is much more divergent between different cohorts than between probands 21 and siblings in the same cohort; 2) the exome-seq assay and raw data processing 22 procedures differ between the two studies. Autism genetic association dissected across multiple levels 6 In this and following sections, we work with the SSC data only unless noted otherwise. 7 The study is well controlled with simple data structure 10 0.60) (row 3 in Fig. 2 ). 10 11 We proposed a gene+pathway dual-hit (or two-factor) model for ASD genetic association 12 based on our results above ( Fig. 2 column 3 ): disrupting effect on target genes (G) and 13 hitting the relevant pathways or not (P). These two factors have significant association 14 with ASD both marginally and conditionally as described above. In our model, variant 
18
There is also significant interaction between gene and pathway factors ( Table S1 ). Text Section 2).
38
.
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052878 doi: bioRxiv preprint first posted online May. 11, 2016; Pathways of DN events, integrated molecular mechanism 1 Selected by our special pathway-level testing procedure, these pathways form a novel, 2 coherent yet non-redundant set of ASD disease mechanisms (Table 1) . These pathways 3 are novel in multiple aspects: 1) first time report the target pathway is involved in ASD 4 (Actin, MAPK, T-junction), 2) there are some evidence in literature, but this is the first 5 report based on whole exome/genome analysis with statistical significance (Lysine, 6 GABA, Wnt, Circ, Glut); 3) for all pathways, this is the first report with pathway graphs 7 on detailed molecular mechanisms for ASD; 4) mostly being causal, they may also 8 explain associated symptoms of ASD, including intellectual disability 18 (Glut, GABA), 9 sleeping 19 (Circ) and digestive 20 (digestion) problems. 10 Importantly, the pathway graphs integrate disease variants and genes from multiple 11 datasets: SSC 10 , ASC 11 or SFARI Gene database 21 (Fig. 4, Fig. S4 ). These pathways are 12 likely true and primary molecular mechanism for ASD as they are consistently selected in 13 these independent analyses. These analyses agree in details too: they frequently converge 14 to the same genes, gene groups (nodes) or the same signaling branch in a pathway. In addition, all aspects or steps of canonical Wnt signaling are involved in ASD (Fig. 4a) . 
21
In probands, missense variants hit the relevant functions or domains in selected pathways. In opposite, missense variants in siblings often hit the non-functional regions or the less 32 relevant regions or genes ( Fig. S8-10 ).This probands-sibling difference is significant 33 overall ( Fig. 4b) and extremely so in the example pathways (Fig. S8-9 We identified subpathway clusters of missense events in probands. Each event cluster 5 hits multiple interacting genes along the pathway. They reveal novel and critical 6 molecular modules in ASD biology. 7 One cluster hit the cAMP second-messenger system 22 in the Glutamatergic synapse 8 pathway (Fig. 4d, Fig. S7) . Two types of G proteins bind and control Adenylate cyclase 9 (AC), Gs activates while Gi/o (Gi/Go) inhibits it (green dashed box in Fig. S7 ). As shown 10 in Fig. 4d , the G-alpha domains of GNAS (Gs) and GNAO1 (Gi/o) are similar and align 11 seamlessly in 3D 23 . They compete to bind to AC C2A domain the same way. Missense 12 variants in these two genes both hit the G-alpha domain, which affect their binding to AC 13 hence AC's catalytic activity on cAMP production and downstream signal. In parallel, 14 the two missense events on AC (ADCY5) hit its C1A domain, which perturb AC's 15 catalytic function too (Fig. 4d ). In the direct upstream (Fig. S7 ), GRM5 (mGluR5) was 16 hit by a destructive in frame deletion (K679) ( Table S5 ). GRM7 (mGluR7) was hit by a 17 missense at the 7 transmembrane region (Fig. 4c) , which likely render it a strong 18 antagonist of the transmembrane signal as an unbounded cytosol form.
19
In another cluster, GRK inhibits mGluR signaling by sequestering heterotrimeric G 
21
All these subpathway level biological stories we present above reveals coherent fine 22 details on ASD mechanism. This is consistent with yet complement to the integrated 23 pathway graphs (Fig. 3 and Fig. S6-7 ).
24
Superpathway biology, emergent big picture 25 The selected pathways are distinct yet highly interconnected. For example, MAPK feed 26 into canonical Wnt pathway and inhibit TCF/LEF dependent transcription ( Fig. 3a and   27 Fig . S4c ). In addition, they also share numerous other connections. For example, Wnt and 28 MAPK are both involved in adherens junctions and focal adhesion (Fig. S4g-4h modules. There is 1 less prominent theme: transcription (not shown in Fig. 5 ). Both Wnt 4 and MAPK pathways end at target gene transcription, which involves chromatin 5 modification, especially histone lysine methylation branch of Lysine degradation (Table   6 1). We also did a parallel GO term analysis, which converges to the same set of 7 biological themes (Supplementary text section 5 and Fig. S12 ). 8 All mutated pathways or functions converge to synapse biology. Either synaptic function, 9 morphology or plasticity (as indicated by transcription 24, 25 ) is disrupted in these cases. 10 Therefore, ASD is a multi-pathway disease not just multi-genic, and ultimately a synapse 11 disease.
12
Discussion
13
We conduct an integrated analysis on ASD exome mutations across multiple levels.
14 These isolated and rarely occurred events are actually connected and recurrent at higher 15 (gene and pathway) levels (Fig. 1) . In the meantime, the otherwise random and divergent 16 results become reproducible between independent studies. This cross-validation not only 17 confirms our results but also justifies our multi-level analysis approach. This novel 18 approach is equally applicable to other complex diseases.
20
We also did a multi-level association analysis, and proposed a gene+pathway dual-hit 21 model for ASD risk (Fig. 2) . The disease variants need to both: 1) disrupt the target genes; We reconstruct a set of coherent and systematic molecular mechanisms for ASD (Fig. 3-5, 30 Table 1 ). Importantly, we discover whole pathways or molecular systems that cause the 31 disease, as supported by multiple independent datasets. These disease pathways not just 32 present a catalog of ASD genetic associations (Table S5) , but further connect hundreds of 33 interacting genes and variants into a whole, dynamic multiscale system (Fig. 3-5 Variants were divided into 3 major categories based on their effects on the target genes.
12
Silent group includes all synonymous variants and those fall in the 3'UTR, 5'UTR, 13 intergenic, intron, and non-coding regions; Missense group include missense variants; 14 LGD (likely gene disrupting) or LoF (lose of function) group includes exon indels (both 15 frame-shift and no-frame-shift), nonsense, and splice-site variants. Variants are selected 16 for gene and pathway level analyses based on a few criteria:1) LGD (or LoF) and 17 missense only, as silent variants are usually not damaging, and have little disease 18 association as a group (Fig. 2) ; 2) For SSC study 10 , we only consider validated variants, Due to different study designs and data quality, we used slightly different criteria for the 29 two cohorts. In SSC, we take w j =1/n j ( number of selected variants occurred to patient i) 30 and s 0 =0.5, while in ASC w j =1 and s 0 =2.
31
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Pathway level analysis 1 We selected pathways enriched for the selected genes. We test for both marginal and 2 conditional overrepresentation given the previously selected pathways. This procedure 3 ensures that pathways selected are drivers instead of passengers, which share genes with 4 the former. 5 6 The analysis is an application of the set theory. Here hyperG is the hypergeometric distribution, and PhyperG is the standard probability 25 mass function of the hypergeometric distribution.
26
The same analysis procedure was applied to KEGG pathways and GO terms. The The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052878 doi: bioRxiv preprint first posted online May. 11, 2016; 13 missense) groups, as described above. At pathway level, they either belong to the 1 Selected pathways or Others. 2 The ASD association of these variant groups can be measured by rate difference (over 3 noise), rate ratio (θ) or log θ between probands and siblings. To test the rate difference 4 between probands and siblings, we conducted two proportion z-test for conditional rates, 5 and two sample t-test for marginal rates. Odd ratio tests gave similar results as in our 6 conditional rate tests, but is not suitable for marginal tests on absolute variant rates. 7 Pathway data integration and visualization 8 Pathview package 26 was used for pathway based data integration and visualization. Variants were first mapped to the target genes, which are then mapped and visualized 10 onto the selected KEGG pathway graphs. In disease gene view (Fig. 3, Fig. S4 Table S4 for full lists of selected variants and genes.
. CC-BY-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052878 doi: bioRxiv preprint first posted online May. 11, 2016; Figure 1 Multi-level comparison of DN mutations between or within ASD whole exome studies. Venn diagrams and test statistics on overlap a) between SSC and ASC ASD cohorts, and b) between probands and siblings of SSC, at different levels. Correlation of pathway analysis statistics c) between SSC and ASC ASD cohorts, and d) between probands and siblings of SSC. Term "considered" or "selected" refers to items before or after selection process at each level (Methods). See Table S4 for full lists of selected variants and genes used in the analysis. LGD and Nonsilent (Missense + LGD) (details in Methods), and pathway level effects (P): hitting Selected pathways or Others. The associations marked in column 3 should be taken as the theme for corresponding row. Notation α(G; A) and α(G; A |P) are read as marginal association between G and A, and their conditional association given P. The association can be measured by rate difference (over noise), rate ratio (θ) or log θ. P-values comes from the rate difference tests. Error bars represent standard error of the mean (SEM).
. Figure S6-7) ; d) 1 and 3D protein structures and missense variants hitting the Adenylate cyclase (AC), i.e. ADCY5, and interacting G proteins, GNAS (Gs) and GNAO1 (Gi/o). The pathway context is shown in the green dashed box in in Supplementary Fig. 7 . AC controls the production of cAMP second-messenger in synapse (Supplementary Text Section 4) . Error bars represent standard error of the mean (SEM).
CC-BY-ND
. CC-BY-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052878 doi: bioRxiv preprint first posted online May. 11, 2016; . CC-BY-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052878 doi: bioRxiv preprint first posted online May. 11, 2016; 
